Marker Therapeutics, Inc. announced the appointment of Katharine Knobil, M.D., to the company's Board of Directors. Dr. Knobil currently serves as Chief Medical Officer at Agilent Technologies, Inc. Prior to Agilent, she served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences, Inc. She currently serves on the Board of Directors of Arena Pharmaceuticals, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.22% | -1.89% | -24.55% |
May. 15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.55% | 36.55M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Marker Therapeutics, Inc. Appoints Katharine Knobil, M.D., to Board of Directors